April 26, 2018 2:33 PM ET

Pharmaceuticals

Company Overview of Arbor Pharmaceuticals, LLC

Company Overview

Arbor Pharmaceuticals, LLC, a specialty pharmaceutical company, researches, develops, manufactures, and commercializes prescription products for cardiovascular, hospital, neuroscience, and pediatric markets. The company develops new chemical entities, as well as already approved molecules for new indications or in improved dosage forms. It offers nitroglycerin lingual sprays for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease; angiotensin II receptor blockers that help blood vessels relax so that blood flows through them freely; and isosorbide dinitrate/hydralazine HCL for the treatment of heart failure. The company also provides carmustine implants...

Six Concourse Parkway

Suite 1800

Atlanta, GA 30328

United States

Founded in 2006

Phone:

678-334-2420

Fax:

470-235-2403

Key Executives for Arbor Pharmaceuticals, LLC

Chief Executive Officer, President and Director
Age: 65
Chief Financial Officer
Chief Compliance Officer, Vice President and General Counsel
Age: 48
Head of Business Development
Vice President of Commercial Operations
Age: 50
Compensation as of Fiscal Year 2017.

Arbor Pharmaceuticals, LLC Key Developments

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur, Triptorelin 6-Month Formulation, for Treatment of Central Precocious Puberty

Arbor Pharmaceuticals, LLC and Debiopharm International SA, part of Debiopharm Group announced that Triptodur™ (triptorelin) is now commercially available in the U.S. for the treatment of pediatric patients 2 years and older diagnosed with central precocious puberty (CPP) -a rare condition that affects one in every 5,000 to 10,000 children. Triptodur™ has been approved by the U.S. Food and Drug Administration for the treatment of children with CPP. In a phase III clinical trial, Triptodur™ (triptorelin) demonstrated a return to pre-pubertal luteinizing hormone (LH) levels in 93% of patients after 6 months of treatment, and in 98% of patients after 12 months. The most common adverse reactions in clinical studies were injection site reactions, menstrual bleeding, hot flush, headache, cough, and infections. Triptorelin extended release formulations were developed by Debiopharm and are manufactured in Switzerland by Debiopharm Research & Manufacturing SA. Arbor acquired exclusive U.S. commercial rights to Triptorelin 6-month for CPP in November 2015 and it was approved by the U.S. FDA in June 2017.

Arbor Pharmaceuticals, LLC Launches New Nymalize® (nimodipine) Oral Solution 10 mL (30 mg) Unit Dose for the Treatment of Subarachnoid Hemorrhage

Arbor Pharmaceuticals, LLC announced that Nymalize® (nimodipine) Oral Solution will now be available in a 10 mL (30 mg) unit dose cup. This new packaging option is designed specifically for patients whom require a dosage that is lower than the standard 20 mL (60 mg) dose. Nymalize provides accurate, consistent dosing in a ready-to-use form for subarachnoid hemorrhage (SAH) patients who cannot swallow capsules. Nymalize is the first and only nimodipine oral solution indicated for the improvement of neurological outcome in adult patients with SAH1 and is available as a 473 mL (16 oz) bottle and as a carton of twelve individually wrapped 10 mL (30 mg) or 20 mL (60 mg) unit dose cups. Packaging of Nymalize meets the medication-storage provision of The Joint Commission on Accreditation of Healthcare. The product was approved by the U.S. Food and Drug Administration (FDA) in 2013 following a fast track designation and priority review.

Investors Reportedly Seeks To Acquire Arbor Pharmaceuticals

Fosun International Limited (SEHK:656) and Shanghai Pharmaceuticals Holding Co., Ltd. (SHSE:601607) are among bidders for a stake in Arbor Pharmaceuticals, LLC, according to people with knowledge of the matter. Fosun and Shanghai Pharma are among potential acquirers competing to buy a stake of at least 20% to 30%, the people said, asking not to be identified because the matter is confidential. The holding in Arbor Pharmaceuticals backed by KKR & Co. L.P. could fetch around $600 million to $700 million, the people said. Representatives for Shanghai Pharma and Fosun Pharma declined to comment. A representative for Arbor didn’t immediately respond to a request for comment.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Arbor Pharmaceuticals, LLC, please visit www.arborpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.